<DOC>
	<DOCNO>NCT00000823</DOCNO>
	<brief_summary>To determine relative antiviral activity safety zidovudine ( AZT ) didanosine ( ddI ) alone combination , well various sequence administration . The relative efficacy approve antiretrovirals early HIV-1 disease unclear ; thus , study need evaluate ability various nucleoside analog limit pathogenicity .</brief_summary>
	<brief_title>A Multicenter Phase II Double-Blind Exploratory Study Evaluate Differences Among Various Zidovudine/Didanosine Regimens Quantitative Measures Viral Burden Relatively Early HIV-1 Infection</brief_title>
	<detailed_description>The relative efficacy approve antiretrovirals early HIV-1 disease unclear ; thus , study need evaluate ability various nucleoside analog limit pathogenicity . Patients undergo observation 2 week , randomize one six treatment arm receive ddI alone sequence combination AZT 16-32 week , follow 4 week post-treatment evaluation . The regimen : ddI alone 32 week ; AZT 16 week follow ddI 16 week ; AZT 16 week follow AZT/ddI combination 16 week ; ddI 16 week follow AZT 16 week ; AZT/ddI combination 32 week ; placebo 32 week . PER AMENDMENT 6/18/96 : NOTE : Patients enrol version 3 study terminate treatment week 16 4 week follow .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Patients must : HIV1 seropositivity . CD4 count &gt; = 550 cells/mm3 . Asymptomatic disease . No prior antiretroviral therapy . Consent parent guardian le 18 year old . PER AMENDMENT 6/18/96 : Patients undocumented history oral candidiasis history candidiasis antibiotic associate may enroll . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Medical condition precludes study compliance . Concurrent Medication : Excluded : Antiretrovirals study drug . Biologic response modifier include erythropoietin GCSF . Systemic corticosteroid . Systemic cytotoxic chemotherapy . Intravenous pentamidine . Concurrent Treatment : Excluded : Systemic radiation therapy . Patients follow prior condition exclude : History grade 2 bad peripheral neuropathy . History pancreatitis factor predispose pancreatitis . Prior Medication : Excluded : Prior antiretrovirals . Systemic immunomodulators ( e.g. , gp120 , gp160 , IL2 , interferon ) within 3 month prior study entry . Chronic alcoholism .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Didanosine</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>Drug Administration Schedule</keyword>
</DOC>